22:45 , Sep 13, 2018 |  BC Week In Review  |  Financial News

ProQR raises $90.6M in upsized offering

ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $104.1 million on Sept. 11 through the sale of 6.6 million shares at $15.75 in a bumped-up follow-on underwritten by Citigroup, Evercore ISI, RBC Capital Markets, H.C. Wainwright and Chardan....
17:36 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

Keeping CRISPR on target

Editas Medicine Inc. (NASDAQ:EDIT) has developed an...
18:14 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

ProQR planning pivotal trial of vision loss candidate

ProQR Therapeutics N.V. (NASDAQ:PRQR) said it plans to start the pivotal Phase II/III ILLUMINATE trial of QR-110 next half to treat Leber congenital amaurosis type 10 (LCA10) caused by the p.Cys998X mutation in the centrosomal...
18:05 , Sep 7, 2018 |  BC Week In Review  |  Financial News

ProQR raises $90.6M in upsized offering

RNA therapy company ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $90.6 million on Sept. 7 through the sale of 5.8 million shares at $15.75 in a bumped-up follow-on underwritten by Citigroup, Evercore ISI, RBC Capital Markets, H.C....
17:59 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Vertex becomes first U.S. company to enter clinic with CRISPR therapy

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and partner CRISPR Therapeutics AG (NASDAQ:CRSP) have begun enrolling patients in the first U.S. company-sponsored trial using CRISPR/Cas9 editing. The European Phase I/II trial is evaluating CTX001, which comprises autologous CRISPR-modified...
14:57 , Sep 7, 2018 |  BC Extra  |  Financial News

After shares spike, ProQR raises $90.6M in upsized offering

ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $90.6 million through the sale of 5.8 million shares at $15.75 in a bumped-up follow-on underwritten by Citigroup, Evercore ISI, RBC Capital Markets, H.C. Wainwright and Chardan. ProQR gained 121%...
20:49 , Sep 5, 2018 |  BC Extra  |  Clinical News

ProQR planning pivotal trial of vision loss candidate

ProQR Therapeutics N.V. (NASDAQ:PRQR) jumped $9.60 (121%) to $17.55 on Wednesday after the company said it plans to start the pivotal Phase II/III ILLUMINATE trial of QR-110 next half to treat Leber congenital amaurosis type...
20:11 , Aug 31, 2018 |  BC Extra  |  Clinical News

Vertex becomes first U.S. company to enter clinic with CRISPR therapy

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and partner CRISPR Therapeutics AG (NASDAQ:CRSP) have begun enrolling patients in the first U.S. company-sponsored trial using CRISPR/Cas9 editing. The European Phase I/II trial is evaluating CTX001, which comprises autologous CRISPR-modified...
15:27 , Jun 8, 2018 |  BC Week In Review  |  Company News

Opthotech gains gene therapy for ophran vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania. The deal gives the biotech an adeno-associated...
20:58 , Jun 7, 2018 |  BC Extra  |  Company News

Ophthotech gains gene therapy for orphan vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and...